Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2018-03-02 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Change of Adviser
Regulatory Filings Classification · 1% confidence The document is very short (2608 characters) and begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the RNS service. The content announces a 'Change of Adviser' (Beaufort Securities Limited has ceased to act as joint broker). This type of specific, non-financial, operational announcement that is distributed via the RNS system and does not fit into the more specific categories (like ER, 10-K, DIV, etc.) is best classified as a general Regulatory Filing, or RNS, as per the provided definitions and the 'MENU VS MEAL' rule (it's an announcement, not the full report itself). Since 'RNS' is explicitly defined as the fallback for miscellaneous regulatory filings, it is the most appropriate code.
2018-03-02 English
Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Patients
Earnings Release Classification · 1% confidence The document is a press release dated March 02, 2018, issued via GlobeNewswire, announcing top-line data from a Phase 2a clinical trial for a drug candidate (RPL554) in cystic fibrosis patients. It details primary and secondary endpoints (PK/PD profile, FEV1 improvement) and mentions future data expectations (Phase 2b COPD data in Q2 2018). This content structure—announcing specific, time-sensitive clinical trial results and financial/development milestones—is characteristic of an Earnings Release (ER) or a general press release announcing material news. Since it focuses on the immediate release of key financial/clinical results rather than a comprehensive annual review (10-K) or a detailed management discussion (MDA), 'ER' (Earnings Release) is the most appropriate classification for material periodic updates, even if it's not strictly a quarterly earnings report, as it releases key performance indicators (clinical trial results). Given the context of a clinical-stage biopharma company, the release of 'top-line data' functions as their primary periodic performance update. Q1 2018
2018-03-02 English
Verona Pharma plc ("Verona Pharma" or the "Company") Reports Operational Update and Financial Results for Full Year Ended December 31, 2017
Report Publication Announcement Classification · 1% confidence The document is a press release announcing the audited financial results for the full year ended December 31, 2017. It provides key operational and financial highlights, including operating loss and cash position. Crucially, it explicitly states: 'An electronic copy of the annual report and accounts will be made available today on the Company's website' and 'This press release does not constitute an offer to sell...'. This confirms the document is an announcement of the report, not the full annual report itself, fitting the definition of a Report Publication Announcement (RPA). FY 2017
2018-02-27 English
Exercise of Warrants and Total Voting Rights
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and the concluding statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content announces the exercise of warrants, the issuance of new ordinary shares, and the resulting total voting rights figure, which is a standard regulatory disclosure concerning share capital changes. This type of announcement, especially when originating from the RNS system, fits best under the 'Regulatory Filings' category (RNS) as a general regulatory announcement, although it touches upon share capital changes (SHA). Given the context of an RNS announcement detailing share issuance and voting rights updates, RNS is the most appropriate general classification for this type of market notification that isn't a primary financial report or a specific corporate action like a takeover.
2018-02-26 English
Exercise of Warrants and Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement identified by the 'RNS Number' header and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content explicitly details the 'Exercise of Warrants' resulting in new ordinary shares, an application for admission to trading on AIM, and the resulting 'Total Voting Rights' figure. This directly relates to changes in the company's share capital structure and voting rights. While it involves share issuance (SHA), the primary focus and context of the announcement, especially concerning the total voting rights denominator update, aligns closely with Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA). Given the specific mention of warrant exercise leading to new shares and the subsequent update to the total share count used for disclosure rules, 'Share Issue/Capital Change' (SHA) is the most precise fit for the core event described.
2018-02-21 English
Exercise of Warrants and Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is identified by the header 'RNS Number : 3175F' and concludes with 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details the 'Exercise of Warrants and Total Voting Rights' and the resulting change in the total number of ordinary shares in issue. This type of announcement, which reports on share capital changes (warrants exercised leading to new shares) and updates the total voting rights denominator for regulatory disclosure purposes, fits best under Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA). Since it specifically details the issuance of new shares following warrant exercise and updates the total share count, SHA is the most precise fit. However, given the context of an RNS announcement detailing a capital structure change, SHA is appropriate. If SHA wasn't available, it would fall under RNS as a general regulatory filing, but SHA is more specific to the event described.
2018-02-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.